Bicycle Therapeutics Ltd

Healthcare · Biotechnology

3.90$ +2.1% vs. previous close Closing price · As of: Oct 9, 2026

Statements

Balance Sheet

Bicycle Therapeutics Ltd (BCYC) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 607 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet BCYC
Line item	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	74	0.0	–	62	82	78	126	116	110	129	119	170	161	224	226	281	480	460	445	417	411	429	454	639	595	547	1,057	997	957	884	832	764	718	652	607
Current Assets	72	68	–	60	77	70	120	110	104	123	113	164	156	215	218	273	459	430	408	381	369	381	408	603	562	516	1,028	966	929	856	804	739	683	619	575
Cash	68	-68	–	48	63	59	109	96	92	110	97	150	136	196	199	260	439	407	373	361	339	294	340	572	526	457	961	891	880	793	721	648	628	559	510
Cash & Short-Term Investments	68	68	–	48	63	59	109	96	92	110	97	150	136	196	199	260	439	407	373	361	339	294	340	572	526	457	961	891	880	793	721	648	628	559	510
Receivables	3.0	0.0	–	5.3	11	8.3	9.9	11	7.1	9.5	11	8.8	15	14	14	7.7	12	13	26	11	21	77	58	17	24	39	47	58	36	46	61	67	36	41	47
Inventory	0.0	0.0	–	–	0.0	0.0	0.0	–	0.0	–	–	0.0	–	0.0	–	–	–	–	0.0	–	0.0	0.0	–	–	–	0.0	0.0	-58	–	–	–	–	–	–	–
Property, Plant & Equipment	1.4	0.0	–	–	1.8	4.4	4.4	4.3	4.3	4.0	3.8	3.5	3.6	6.3	5.9	5.7	18	26	32	30	33	–	34	30	–	–	–	–	–	–	–	–	–	–	–
Goodwill	0.0	0.0	–	–	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	0.0	0.0	–	–	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	9.5	0.0	–	7.7	151	21	22	21	17	47	48	61	66	82	84	111	134	129	134	128	140	186	234	223	224	191	184	166	164	144	163	145	108	98	96
Current Liabilities	9.5	0.0	–	7.7	8.9	8.4	9.4	8.8	8.8	16	17	17	23	21	23	30	36	35	41	42	53	53	72	70	70	50	70	56	67	58	77	69	57	49	48
Short-Term Debt	0.0	0.0	–	–	6.9	0.6	0.6	0.6	0.6	0.6	0.7	0.7	0.8	0.7	0.8	0.8	2.4	3.0	2.9	2.8	3.1	4.7	4.7	4.7	4.9	5.0	28	5.6	5.5	5.7	5.4	4.8	2.8	1.5	–
Accounts Payable	2.1	0.0	–	1.1	1.9	2.2	2.6	2.0	1.9	4.4	3.3	2.1	1.4	1.0	3.5	1.8	2.7	4.0	4.9	7.1	6.5	2.8	5.3	8.5	13	7.1	7.5	5.7	16	11	18	13	9.7	6.0	5.7
Long-Term Debt	0.0	0.0	–	–	0.0	1.8	–	–	–	–	–	14	15	29	30	30	30	30	30	30	30	30	31	31	31	31	8.5	–	–	–	–	–	–	–	–
Shareholders' Equity	49	49	–	29	-70	57	105	95	93	82	71	110	95	142	142	171	346	330	311	289	271	243	220	416	371	356	874	831	793	740	669	618	610	554	510
Retained Earnings	-48	0.0	–	-63	-70	-76	-87	-96	-101	-112	-124	-134	-152	-168	-186	-200	-218	-246	-273	-301	-331	-370	-413	-463	-512	-538	-578	-629	-681	-742	-820	-880	-900	-961	-1,011
Shares Outstanding	15	13	13	13	13	18	7.3	18	18	18	18	19	21	22	24	25	29	30	30	30	30	30	30	40	42	43	52	69	69	69	69	69	69	70	70

Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings